NovoCure Limited
NVCR
Positions held
Your positionsNVCR isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- NovoCure operates in the innovative medical devices sector, focusing on tumor treatment with its proprietary TTFields technology, which positions it well against competitors in the oncology space.
- Revenue increased by 5% compared to the prior quarter, reaching $184 million.
- Gross margin remained stable at 77.6%, indicating strong product profitability.
- The company has a negative profit margin of -21.25%, reflecting ongoing financial challenges.
- Net income for 2025 was -136.227 million, showing continued losses year over year.
- The stock has a 'Strong Sell' signal with a score of -16.00, indicating bearish market sentiment.
Fundamentals
| Market cap | $1.66B | Enterprise value | $1.45B | Trailing P/E | — | Forward P/E | -17.42 |
| PEG | — | Price / book | 4.90 | Beta | 0.99 | Dividend yield | 0.00% |
| Revenue growth | 15.6% | Earnings growth | — | Gross margin | 76.4% | Operating margin | -5.8% |
| Profit margin | -21.2% | ROE | -43.2% | ROA | -9.3% | Debt / equity | 0.69 |
| Current ratio | 2.89 | Free cash flow | $22.76M | Analyst recommendation | buy | Mean target | $26.86 |
| 52w high | $21.45 | 52w low | $9.82 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $184M | $174M | $174M | $167M | $159M |
| Op margin | -5.8% | -38.7% | -23.2% | -21.5% | -24.9% |
| Net income | -$15.7M | -$71.1M | -$24.5M | -$37.3M | -$40.1M |
| Gross margin | 77.6% | 77.6% | 75.8% | 73.2% | 73.9% |
| Gross profit | $142M | $135M | $132M | $122M | $117M |
| Operating income | -$10.6M | -$67.4M | -$40.4M | -$36.0M | -$39.5M |
- Revenue +5% vs prior quarter ($184M vs $174M).
- Gross margin 77.6% (was 77.6% prior quarter).
- Operating margin expanded to -5.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $655M | $605M | $509M | $538M |
| Op margin | -23.5% | -28.2% | -45.7% | -16.6% |
| Net income | -$136M | -$169M | -$207M | -$92.5M |
| Gross margin | 74.5% | 77.3% | 74.8% | 78.6% |
| Gross profit | $488M | $468M | $381M | $423M |
| Operating income | -$154M | -$170M | -$233M | -$89.5M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Novocure to Report Third Quarter 2026 Financial Results
2026-09-23 · NovoCure (NVCR) Stock Still Looks Cheap After Its 86% Fall
2026-09-23 · NovoCure (NVCR) Could Be 36% Undervalued Despite Its Recent Board Change
2026-09-18 · NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even
2026-09-07 · Novocure Reports Patient Data Exposure in Cybersecurity Incident
2026-09-02 · Novocure Announces Upcoming Investor Events
2026-08-28 · Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
2026-08-20 · Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice
2026-08-14 · Which Medtech Giant Would Buy Inspire Medical Systems?
2026-08-12 · Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet
2026-08-07 · 4 Healthcare Stocks to Watch as Defensive Demand Strengthens
Price (daily)
Full chart · RSI · MACD · patterns